PARP inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Matthew A. Powell, Lars Christian Hanker, Sharad Ghamande, Kristina Lindemann, Lucy Gilbert, Ana Oaknin, Destin R. Black, Antonella Savarese, Angeles Alvarez Secord, Rebecca Sophie Kristeleit, Robert Holloway, Jacqueline Maria Tromp
+8 more Joseph Buscema, Toon Van Gorp, Johanne Ingrid Weberpals, Siarhei A. Mavrichev, Kaitlin Yablonski, Laura Austin, Sudarshan Kumar Sharma, Trine Jakobi Nøttrup
DOI: 10.1016/j.ijgc.2025.103031
Cited by: 1

Fields of Study & Subjects

PARP inhibition in cancer therapy Endometrial and Cervical Cancer Treatments Ovarian cancer diagnosis and treatment

Publication details

Journal / source
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Volume
36
Issue
2
Pages
103031–103031
Publication date
1 February 2026
Language
EN